Trial Outcomes & Findings for SECURE, the Cimzia ® Crohn's Disease Post-Marketing Registry (NCT NCT00844285)

Last Updated: 2023-05-06

Results Overview

Incidence rate is defined as the number of participants experiencing the event of interest divided by the number person-years without an event (time up to the event for participants experiencing an event, and the full study time for those without). Adverse events of interest included malignant or unspecified tumor, serious infections, opportunistic infections, serious cardiovascular events, congestive heart failure, demyelinating-like disorders, aplastic anemia, pancytopenia, thrombocytopenia, neutropenia, leucopenia, serious bleeding events, lupus and lupus-like illness, serious skin reactions, hepatic events, hypersensitivity reactions and anaphylactic reactions, malignant lymphomas, non-melanoma skin cancer, autoimmune disorders. Treatment groups are based upon actual treatment conservatively assigning participant time and events to CZP even after stopping CZP. Data for malignant or unspecified tumor as per malignancy rules has been reported in this outcome measure.

Recruitment status

COMPLETED

Target enrollment

3072 participants

Primary outcome timeframe

Baseline up to 10 years

Results posted on

2023-05-06

Participant Flow

The study started to enroll study participants in January 2009 and concluded in August 2020.

Participant flow refers to the Enrolled Set.

Participant milestones

Participant milestones
Measure	Cimzia at Baseline Participants who received Cimzia® up to 70 days prior to Baseline.	No Cimzia at Baseline Participants not in the Cimzia® at Baseline group receiving corticosteroids, immunosuppressants or other biologics (e.g. anti-TNFs) other than Cimzia® at Baseline.	Gap (No Cimzia and no Comparator at Baseline) Participants who did not receive Cimzia® within 70 days prior to Baseline nor corticosteroids, immunosuppressants or other biologics (e.g. anti-TNFs) other than Cimzia® at Baseline.
Overall Study STARTED	1131	1666	275
Overall Study COMPLETED	42	62	3
Overall Study NOT COMPLETED	1089	1604	272

Reasons for withdrawal

Reasons for withdrawal
Measure	Cimzia at Baseline Participants who received Cimzia® up to 70 days prior to Baseline.	No Cimzia at Baseline Participants not in the Cimzia® at Baseline group receiving corticosteroids, immunosuppressants or other biologics (e.g. anti-TNFs) other than Cimzia® at Baseline.	Gap (No Cimzia and no Comparator at Baseline) Participants who did not receive Cimzia® within 70 days prior to Baseline nor corticosteroids, immunosuppressants or other biologics (e.g. anti-TNFs) other than Cimzia® at Baseline.
Overall Study Lost to Follow-up	330	486	74
Overall Study Other	0	1	0
Overall Study Other than specified	95	129	12
Overall Study Site closure	256	450	50
Overall Study Follow-up < 8 years	16	23	4
Overall Study Protocol Violation	26	28	54
Overall Study Death	22	21	8
Overall Study Withdrew Consent	344	466	70

Baseline Characteristics

SECURE, the Cimzia ® Crohn's Disease Post-Marketing Registry

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Cimzia at Baseline n=1131 Participants Participants who received Cimzia® up to 70 days prior to Baseline.	No Cimzia at Baseline n=1666 Participants Participants not in the Cimzia® at Baseline group receiving corticosteroids, immunosuppressants or other biologics (e.g. anti-TNFs) other than Cimzia® at Baseline.	Gap (No Cimzia and no Comparator at Baseline) n=275 Participants Participants who did not receive Cimzia® within 70 days prior to Baseline nor corticosteroids, immunosuppressants or other biologics (e.g. anti-TNFs) other than Cimzia® at Baseline.	Total n=3072 Participants Total of all reporting groups
Age, Categorical <=18 years	34 Participants n=5 Participants	71 Participants n=7 Participants	10 Participants n=5 Participants	115 Participants n=4 Participants
Age, Categorical Between 18 and 65 years	1018 Participants n=5 Participants	1510 Participants n=7 Participants	222 Participants n=5 Participants	2750 Participants n=4 Participants
Age, Categorical >=65 years	79 Participants n=5 Participants	85 Participants n=7 Participants	43 Participants n=5 Participants	207 Participants n=4 Participants
Age, Continuous	39.8 years STANDARD_DEVIATION 14.9 • n=5 Participants	39.2 years STANDARD_DEVIATION 14.9 • n=7 Participants	45.0 years STANDARD_DEVIATION 17.8 • n=5 Participants	40.0 years STANDARD_DEVIATION 15.3 • n=4 Participants
Sex/Gender, Customized Female	706 Participants n=5 Participants	924 Participants n=7 Participants	166 Participants n=5 Participants	1796 Participants n=4 Participants
Sex/Gender, Customized Male	425 Participants n=5 Participants	740 Participants n=7 Participants	104 Participants n=5 Participants	1269 Participants n=4 Participants
Sex/Gender, Customized Missing	0 Participants n=5 Participants	2 Participants n=7 Participants	5 Participants n=5 Participants	7 Participants n=4 Participants
Race/Ethnicity, Customized American Indian /Alaskan native	2 Participants n=5 Participants	4 Participants n=7 Participants	1 Participants n=5 Participants	7 Participants n=4 Participants
Race/Ethnicity, Customized Asian	13 Participants n=5 Participants	19 Participants n=7 Participants	3 Participants n=5 Participants	35 Participants n=4 Participants
Race/Ethnicity, Customized Black	82 Participants n=5 Participants	117 Participants n=7 Participants	13 Participants n=5 Participants	212 Participants n=4 Participants
Race/Ethnicity, Customized Native Hawaiian or other Pacific Islander	1 Participants n=5 Participants	2 Participants n=7 Participants	4 Participants n=5 Participants	7 Participants n=4 Participants
Race/Ethnicity, Customized White	1017 Participants n=5 Participants	1480 Participants n=7 Participants	243 Participants n=5 Participants	2740 Participants n=4 Participants
Race/Ethnicity, Customized Other/mixed	14 Participants n=5 Participants	35 Participants n=7 Participants	5 Participants n=5 Participants	54 Participants n=4 Participants
Race/Ethnicity, Customized Missing	1 Participants n=5 Participants	2 Participants n=7 Participants	6 Participants n=5 Participants	9 Participants n=4 Participants
Race/Ethnicity, Customized Hispanic or Latino	44 Participants n=5 Participants	79 Participants n=7 Participants	19 Participants n=5 Participants	142 Participants n=4 Participants
Race/Ethnicity, Customized Not Hispanic or Latino	1086 Participants n=5 Participants	1585 Participants n=7 Participants	250 Participants n=5 Participants	2921 Participants n=4 Participants

PRIMARY outcome

Timeframe: Baseline up to 10 years

Population: Enrolled set was defined as all participants enrolled and with an informed consent. Here, "Number of Participants Analyzed" included those who were evaluable for this outcome measure. Participants were counted in more than one arm based on the various treatments they actually received and presented. Based upon planned analysis, data is reported for Cimzia® and Comparator reporting groups only.

Outcome measures

Outcome measures
Measure	Cimzia n=1463 Participants Participants (exposure and events) are conservatively included in this group from the time of first administration of Cimzia® until the end of the study even if they switch to comparator. Participants may be included in other treatment groups.	Comparator n=1887 Participants Participants (exposure and events) are included in this group from the time of first administration of comparator until the end of the study or switch to Cimzia®, a participant cannot be in the comparator group if their first treatment in the study was Cimzia®. Participants may be included in other treatment groups.	Overlap Participants (exposure and events) while receiving Cimzia® along with corticosteroids, immunosuppressants or other biologics (e.g. anti-TNFs) other than Cimzia® including the half-life time of Cimzia® and the comparator. Participants may be included in other treatment groups.	Gap (No Cimzia and no Comparator at Baseline) Participants (exposure and events) neither receiving Cimzia® (including the half-life of Cimzia®) nor receiving comparator (including the half-life). Participants may be included in other treatment groups.	Cimzia + Overlap Participants who received Cimzia® monotherapy or Cimzia® in combination with comparison treatment were included in this group. Participants may be included in other treatment groups.
Incidence of Adverse Events of Interest Per 100 Participants-Years By Actual Treatment (Malignancy Rules)	0.45 no. of events per 100 participant-years Interval 0.31 to 0.65	0.65 no. of events per 100 participant-years Interval 0.48 to 0.86	—	—	—

PRIMARY outcome

Timeframe: Baseline up to 10 years

Incidence rate is defined as the number of participants experiencing the event of interest divided by the number person-years without an event (time up to the event for participants experiencing an event, and the full study time for those without an event of interest). Adverse events of interest (AEoI) included malignant or unspecified tumor, serious infections, opportunistic infections, serious cardiovascular events, congestive heart failure, demyelinating-like disorders, aplastic anemia, pancytopenia, thrombocytopenia, neutropenia, leucopenia, serious bleeding events, lupus and lupus-like illness, serious skin reactions, hepatic events, hypersensitivity reactions and anaphylactic reactions, malignant lymphomas, non-melanoma skin cancer, autoimmune disorders. Data for AEoIs as per acute event rules has been reported in this outcome measure where the AEoI is assigned to the treatment the participant is on at the time of the event.

Outcome measures

Outcome measures
Measure	Cimzia n=824 Participants Participants (exposure and events) are conservatively included in this group from the time of first administration of Cimzia® until the end of the study even if they switch to comparator. Participants may be included in other treatment groups.	Comparator n=2478 Participants Participants (exposure and events) are included in this group from the time of first administration of comparator until the end of the study or switch to Cimzia®, a participant cannot be in the comparator group if their first treatment in the study was Cimzia®. Participants may be included in other treatment groups.	Overlap n=1165 Participants Participants (exposure and events) while receiving Cimzia® along with corticosteroids, immunosuppressants or other biologics (e.g. anti-TNFs) other than Cimzia® including the half-life time of Cimzia® and the comparator. Participants may be included in other treatment groups.	Gap (No Cimzia and no Comparator at Baseline) n=1022 Participants Participants (exposure and events) neither receiving Cimzia® (including the half-life of Cimzia®) nor receiving comparator (including the half-life). Participants may be included in other treatment groups.	Cimzia + Overlap n=1428 Participants Participants who received Cimzia® monotherapy or Cimzia® in combination with comparison treatment were included in this group. Participants may be included in other treatment groups.
Incidence of Adverse Events of Interest Per 100 Participant-Years By Actual Treatment (Acute Event Rules) Malignant or Unspecified Tumor	0.35 no. of events per 100 participant-years Interval 0.12 to 0.83	0.59 no. of events per 100 participant-years Interval 0.44 to 0.77	0.60 no. of events per 100 participant-years Interval 0.28 to 1.15	0.56 no. of events per 100 participant-years Interval 0.29 to 0.97	0.48 no. of events per 100 participant-years Interval 0.26 to 0.81
Incidence of Adverse Events of Interest Per 100 Participant-Years By Actual Treatment (Acute Event Rules) Serious infections	2.03 no. of events per 100 participant-years Interval 1.35 to 2.94	1.59 no. of events per 100 participant-years Interval 1.34 to 1.88	6.15 no. of events per 100 participant-years Interval 4.9 to 7.61	1.46 no. of events per 100 participant-years Interval 0.98 to 2.08	4.08 no. of events per 100 participant-years Interval 3.36 to 4.91
Incidence of Adverse Events of Interest Per 100 Participant-Years By Actual Treatment (Acute Event Rules) Opportunistic infections	0.14 no. of events per 100 participant-years Interval 0.02 to 0.5	0.08 no. of events per 100 participant-years Interval 0.03 to 0.16	0.20 no. of events per 100 participant-years Interval 0.04 to 0.59	0.09 no. of events per 100 participant-years Interval 0.01 to 0.33	0.17 no. of events per 100 participant-years Interval 0.06 to 0.4
Incidence of Adverse Events of Interest Per 100 Participant-Years By Actual Treatment (Acute Event Rules) Serious cardiovascular events	0.14 no. of events per 100 participant-years Interval 0.02 to 0.5	0.13 no. of events per 100 participant-years Interval 0.07 to 0.23	0.34 no. of events per 100 participant-years Interval 0.11 to 0.78	0.23 no. of events per 100 participant-years Interval 0.07 to 0.53	0.24 no. of events per 100 participant-years Interval 0.1 to 0.49
Incidence of Adverse Events of Interest Per 100 Participant-Years By Actual Treatment (Acute Event Rules) Congestive heart failure	0 no. of events per 100 participant-years Interval 0.0 to 0.0	0.08 no. of events per 100 participant-years Interval 0.03 to 0.15	0.07 no. of events per 100 participant-years Interval 0.0 to 0.37	0 no. of events per 100 participant-years Interval 0.0 to 0.0	0.03 no. of events per 100 participant-years Interval 0.0 to 0.19
Incidence of Adverse Events of Interest Per 100 Participant-Years By Actual Treatment (Acute Event Rules) Demyelinating-like disorders	0 no. of events per 100 participant-years Interval 0.0 to 0.0	0 no. of events per 100 participant-years Interval 0.0 to 0.0	0 no. of events per 100 participant-years Interval 0.0 to 0.0	0 no. of events per 100 participant-years Interval 0.0 to 0.0	0 no. of events per 100 participant-years Interval 0.0 to 0.0
Incidence of Adverse Events of Interest Per 100 Participant-Years By Actual Treatment (Acute Event Rules) Aplastic Anemia, Pancytopenia, Thrombocytopenia, Neutropenia, Leucopenia	0 no. of events per 100 participant-years Interval 0.0 to 0.0	0.08 no. of events per 100 participant-years Interval 0.03 to 0.15	0.27 no. of events per 100 participant-years Interval 0.07 to 0.68	0.14 no. of events per 100 participant-years Interval 0.03 to 0.4	0.14 no. of events per 100 participant-years Interval 0.04 to 0.35
Incidence of Adverse Events of Interest Per 100 Participant-Years By Actual Treatment (Acute Event Rules) Serious bleeding events	0.28 no. of events per 100 participant-years Interval 0.08 to 0.73	0.23 no. of events per 100 participant-years Interval 0.14 to 0.35	0.47 no. of events per 100 participant-years Interval 0.19 to 0.97	0.14 no. of events per 100 participant-years Interval 0.03 to 0.4	0.38 no. of events per 100 participant-years Interval 0.19 to 0.68
Incidence of Adverse Events of Interest Per 100 Participant-Years By Actual Treatment (Acute Event Rules) Lupus and lupus-like illness	0 no. of events per 100 participant-years Interval 0.0 to 0.0	0.06 no. of events per 100 participant-years Interval 0.02 to 0.14	0 no. of events per 100 participant-years Interval 0.0 to 0.0	0 no. of events per 100 participant-years Interval 0.0 to 0.0	0 no. of events per 100 participant-years Interval 0.0 to 0.0
Incidence of Adverse Events of Interest Per 100 Participant-Years By Actual Treatment (Acute Event Rules) Serious skin reactions	0 no. of events per 100 participant-years Interval 0.0 to 0.0	0 no. of events per 100 participant-years Interval 0.0 to 0.0	0 no. of events per 100 participant-years Interval 0.0 to 0.0	0 no. of events per 100 participant-years Interval 0.0 to 0.0	0 no. of events per 100 participant-years Interval 0.0 to 0.0
Incidence of Adverse Events of Interest Per 100 Participant-Years By Actual Treatment (Acute Event Rules) Hepatic Events	0.07 no. of events per 100 participant-years Interval 0.0 to 0.39	0.09 no. of events per 100 participant-years Interval 0.04 to 0.17	0.13 no. of events per 100 participant-years Interval 0.02 to 0.48	0.05 no. of events per 100 participant-years Interval 0.0 to 0.25	0.10 no. of events per 100 participant-years Interval 0.02 to 0.3
Incidence of Adverse Events of Interest Per 100 Participant-Years By Actual Treatment (Acute Event Rules) Hypersensitivity reactions and anaphylactic reactions	0.28 no. of events per 100 participant-years Interval 0.08 to 0.72	0.11 no. of events per 100 participant-years Interval 0.05 to 0.2	0.60 no. of events per 100 participant-years Interval 0.28 to 1.14	0 no. of events per 100 participant-years Interval 0.0 to 0.0	0.44 no. of events per 100 participant-years Interval 0.24 to 0.76
Incidence of Adverse Events of Interest Per 100 Participant-Years By Actual Treatment (Acute Event Rules) Malignant lymphomas	0.07 no. of events per 100 participant-years Interval 0.0 to 0.39	0.04 no. of events per 100 participant-years Interval 0.01 to 0.11	0.13 no. of events per 100 participant-years Interval 0.02 to 0.48	0 no. of events per 100 participant-years Interval 0.0 to 0.0	0.10 no. of events per 100 participant-years Interval 0.02 to 0.3
Incidence of Adverse Events of Interest Per 100 Participant-Years By Actual Treatment (Acute Event Rules) Non-melanoma skin cancer	0.14 no. of events per 100 participant-years Interval 0.02 to 0.51	0.24 no. of events per 100 participant-years Interval 0.15 to 0.36	0.20 no. of events per 100 participant-years Interval 0.04 to 0.59	0.05 no. of events per 100 participant-years Interval 0.0 to 0.25	0.17 no. of events per 100 participant-years Interval 0.06 to 0.4
Incidence of Adverse Events of Interest Per 100 Participant-Years By Actual Treatment (Acute Event Rules) Autoimmune disorders	0.35 no. of events per 100 participant-years Interval 0.11 to 0.82	0.36 no. of events per 100 participant-years Interval 0.25 to 0.5	0.27 no. of events per 100 participant-years Interval 0.07 to 0.69	0.23 no. of events per 100 participant-years Interval 0.07 to 0.53	0.31 no. of events per 100 participant-years Interval 0.14 to 0.59

SECONDARY outcome

Timeframe: Month 6, 12, 18, 24, 30, 36, 42, 48, 54, 60, 66, 72, 78, 84, 90, 96, 102, and 108, compared to Baseline

Population: Enrolled Set was defined as all participants enrolled and with an informed consent. Here, "Number Analyzed" included those who were evaluable at specified time points only.

HBI measured 5 parameters: the general well-being (0= very well to 4= terrible), abdominal pain (0= none to 3= severe), number of liquid stools per day (0 to no maximum score), presence of an abdominal mass on physical exam (0= none to 3= definite and tender), and whether there are any complications \[1 per item: joint pain (arthralgia), eye inflammation (uveitis), red nodules on skin (erythema nodosum), canker sores (aphthous ulcers), skin wound/ulcers (pyoderma gangrenosum), tear in skin of anal area (anal fissure), fluid or pus drainage from anal area (new fistula), and abscess\]. The total HBI score was sum of all the 5 individual parameters, where minimum score was 0 and there was no pre-specified maximum score as it was dependent on the number of liquids stools. Higher HBI scores indicated greater disease activity. A negative change indicated less disease activity.

Outcome measures

Outcome measures
Measure	Cimzia n=1131 Participants Participants (exposure and events) are conservatively included in this group from the time of first administration of Cimzia® until the end of the study even if they switch to comparator. Participants may be included in other treatment groups.	Comparator n=1666 Participants Participants (exposure and events) are included in this group from the time of first administration of comparator until the end of the study or switch to Cimzia®, a participant cannot be in the comparator group if their first treatment in the study was Cimzia®. Participants may be included in other treatment groups.	Overlap n=275 Participants Participants (exposure and events) while receiving Cimzia® along with corticosteroids, immunosuppressants or other biologics (e.g. anti-TNFs) other than Cimzia® including the half-life time of Cimzia® and the comparator. Participants may be included in other treatment groups.	Gap (No Cimzia and no Comparator at Baseline) Participants (exposure and events) neither receiving Cimzia® (including the half-life of Cimzia®) nor receiving comparator (including the half-life). Participants may be included in other treatment groups.	Cimzia + Overlap Participants who received Cimzia® monotherapy or Cimzia® in combination with comparison treatment were included in this group. Participants may be included in other treatment groups.
Change From Baseline in Physician's Harvey Bradshaw Index (HBI) Total Score to Each Post-Baseline Assessment Month 72	-1.9 units on a scale Standard Deviation 4.8	-0.6 units on a scale Standard Deviation 3.7	-1.6 units on a scale Standard Deviation 3.2	—	—
Change From Baseline in Physician's Harvey Bradshaw Index (HBI) Total Score to Each Post-Baseline Assessment Month 78	-1.5 units on a scale Standard Deviation 4.7	-0.6 units on a scale Standard Deviation 4.5	-1.7 units on a scale Standard Deviation 4.2	—	—
Change From Baseline in Physician's Harvey Bradshaw Index (HBI) Total Score to Each Post-Baseline Assessment Month 84	-2.3 units on a scale Standard Deviation 4.9	-0.8 units on a scale Standard Deviation 4.5	-1.2 units on a scale Standard Deviation 4.5	—	—
Change From Baseline in Physician's Harvey Bradshaw Index (HBI) Total Score to Each Post-Baseline Assessment Month 6	-1.1 units on a scale Standard Deviation 4.3	-0.7 units on a scale Standard Deviation 3.8	-1.3 units on a scale Standard Deviation 4.7	—	—
Change From Baseline in Physician's Harvey Bradshaw Index (HBI) Total Score to Each Post-Baseline Assessment Month 12	-1.2 units on a scale Standard Deviation 5.3	-0.8 units on a scale Standard Deviation 3.8	-1.3 units on a scale Standard Deviation 4.9	—	—
Change From Baseline in Physician's Harvey Bradshaw Index (HBI) Total Score to Each Post-Baseline Assessment Month 18	-1.6 units on a scale Standard Deviation 4.6	-0.8 units on a scale Standard Deviation 4.2	-1.8 units on a scale Standard Deviation 5.5	—	—
Change From Baseline in Physician's Harvey Bradshaw Index (HBI) Total Score to Each Post-Baseline Assessment Month 24	-1.9 units on a scale Standard Deviation 4.7	-1.2 units on a scale Standard Deviation 3.7	-1.3 units on a scale Standard Deviation 4.9	—	—
Change From Baseline in Physician's Harvey Bradshaw Index (HBI) Total Score to Each Post-Baseline Assessment Month 30	-1.6 units on a scale Standard Deviation 4.7	-1.1 units on a scale Standard Deviation 3.9	-1.1 units on a scale Standard Deviation 4.5	—	—
Change From Baseline in Physician's Harvey Bradshaw Index (HBI) Total Score to Each Post-Baseline Assessment Month 36	-1.8 units on a scale Standard Deviation 5.2	-1.1 units on a scale Standard Deviation 3.6	-1.9 units on a scale Standard Deviation 5.1	—	—
Change From Baseline in Physician's Harvey Bradshaw Index (HBI) Total Score to Each Post-Baseline Assessment Month 42	-1.6 units on a scale Standard Deviation 5.1	-0.9 units on a scale Standard Deviation 4.1	-2.3 units on a scale Standard Deviation 4.0	—	—
Change From Baseline in Physician's Harvey Bradshaw Index (HBI) Total Score to Each Post-Baseline Assessment Month 48	-1.1 units on a scale Standard Deviation 4.8	-0.8 units on a scale Standard Deviation 3.9	-1.9 units on a scale Standard Deviation 4.0	—	—
Change From Baseline in Physician's Harvey Bradshaw Index (HBI) Total Score to Each Post-Baseline Assessment Month 54	-1.7 units on a scale Standard Deviation 4.8	-0.8 units on a scale Standard Deviation 4.1	-1.2 units on a scale Standard Deviation 4.4	—	—
Change From Baseline in Physician's Harvey Bradshaw Index (HBI) Total Score to Each Post-Baseline Assessment Month 60	-2.0 units on a scale Standard Deviation 4.9	-0.6 units on a scale Standard Deviation 4.0	-1.0 units on a scale Standard Deviation 5.3	—	—
Change From Baseline in Physician's Harvey Bradshaw Index (HBI) Total Score to Each Post-Baseline Assessment Month 66	-1.1 units on a scale Standard Deviation 4.5	-0.8 units on a scale Standard Deviation 4.0	-2.4 units on a scale Standard Deviation 4.6	—	—
Change From Baseline in Physician's Harvey Bradshaw Index (HBI) Total Score to Each Post-Baseline Assessment Month 90	-1.9 units on a scale Standard Deviation 4.7	-0.9 units on a scale Standard Deviation 3.9	-2.0 units on a scale Standard Deviation 3.9	—	—
Change From Baseline in Physician's Harvey Bradshaw Index (HBI) Total Score to Each Post-Baseline Assessment Month 96	-2.4 units on a scale Standard Deviation 4.3	-1.0 units on a scale Standard Deviation 3.8	-1.6 units on a scale Standard Deviation 4.2	—	—
Change From Baseline in Physician's Harvey Bradshaw Index (HBI) Total Score to Each Post-Baseline Assessment Month 102	-1.9 units on a scale Standard Deviation 3.9	-1.6 units on a scale Standard Deviation 3.9	-0.3 units on a scale Standard Deviation 3.0	—	—
Change From Baseline in Physician's Harvey Bradshaw Index (HBI) Total Score to Each Post-Baseline Assessment Month 108	-1.8 units on a scale Standard Deviation 1.9	-0.8 units on a scale Standard Deviation 5.3	0.0 units on a scale Standard Deviation 1.5	—	—

SECONDARY outcome

Timeframe: Month 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75, 78, 81, 84, 87, 90, 93, 96, 99, 102, 105 and 108, compared to Baseline

Population: Enrolled Set was defined as all participants enrolled and with an informed consent. Here, "Number Analyzed" included those who were evaluable at specified time points only.

HBI response determined based on patient reported HBI total scores was defined as a drop of at least 3 points from baseline HBI total score. Patient reported HBI was composed of 4 parameters: the general well-being (0= very well to 4= terrible), abdominal pain (0= none to 3= severe), number of liquid stools per day (0 to no maximum score), and whether there are any complications \[1 per item: joint pain (arthralgia), eye inflammation (uveitis), red nodules on skin (erythema nodosum), canker sores (aphthous ulcers), skin wound/ulcers (pyoderma gangrenosum), tear in skin of anal area (anal fissure), fluid or pus drainage from anal area (new fistula), and abscess\]. The total HBI score was sum of all the 4 individual parameters, where minimum score was 0 and there was no pre-specified maximum score as it was dependent on the number of liquids stools. Higher HBI scores indicated greater disease activity. A negative change indicated less disease activity.

Outcome measures

Outcome measures
Measure	Cimzia n=1131 Participants Participants (exposure and events) are conservatively included in this group from the time of first administration of Cimzia® until the end of the study even if they switch to comparator. Participants may be included in other treatment groups.	Comparator n=1666 Participants Participants (exposure and events) are included in this group from the time of first administration of comparator until the end of the study or switch to Cimzia®, a participant cannot be in the comparator group if their first treatment in the study was Cimzia®. Participants may be included in other treatment groups.	Overlap n=275 Participants Participants (exposure and events) while receiving Cimzia® along with corticosteroids, immunosuppressants or other biologics (e.g. anti-TNFs) other than Cimzia® including the half-life time of Cimzia® and the comparator. Participants may be included in other treatment groups.	Gap (No Cimzia and no Comparator at Baseline) Participants (exposure and events) neither receiving Cimzia® (including the half-life of Cimzia®) nor receiving comparator (including the half-life). Participants may be included in other treatment groups.	Cimzia + Overlap Participants who received Cimzia® monotherapy or Cimzia® in combination with comparison treatment were included in this group. Participants may be included in other treatment groups.
Change From Baseline in Patient's Harvey Bradshaw Index (HBI) Total Score to Each Post-Baseline Assessment Month 3	0.6 units on a scale Standard Deviation 4.4	0.2 units on a scale Standard Deviation 3.5	0.1 units on a scale Standard Deviation 4.7	—	—
Change From Baseline in Patient's Harvey Bradshaw Index (HBI) Total Score to Each Post-Baseline Assessment Month 6	0.2 units on a scale Standard Deviation 4.9	-0.1 units on a scale Standard Deviation 3.8	-0.0 units on a scale Standard Deviation 4.0	—	—
Change From Baseline in Patient's Harvey Bradshaw Index (HBI) Total Score to Each Post-Baseline Assessment Month 9	-0.0 units on a scale Standard Deviation 4.7	0.1 units on a scale Standard Deviation 3.9	-0.1 units on a scale Standard Deviation 4.7	—	—
Change From Baseline in Patient's Harvey Bradshaw Index (HBI) Total Score to Each Post-Baseline Assessment Month 12	-0.5 units on a scale Standard Deviation 4.4	-0.0 units on a scale Standard Deviation 3.8	0.1 units on a scale Standard Deviation 4.6	—	—
Change From Baseline in Patient's Harvey Bradshaw Index (HBI) Total Score to Each Post-Baseline Assessment Month 15	-0.6 units on a scale Standard Deviation 4.4	-0.2 units on a scale Standard Deviation 3.6	-0.5 units on a scale Standard Deviation 4.1	—	—
Change From Baseline in Patient's Harvey Bradshaw Index (HBI) Total Score to Each Post-Baseline Assessment Month 18	-0.7 units on a scale Standard Deviation 4.6	-0.1 units on a scale Standard Deviation 3.6	-0.3 units on a scale Standard Deviation 4.0	—	—
Change From Baseline in Patient's Harvey Bradshaw Index (HBI) Total Score to Each Post-Baseline Assessment Month 21	-0.7 units on a scale Standard Deviation 4.9	-0.2 units on a scale Standard Deviation 3.6	0.3 units on a scale Standard Deviation 5.5	—	—
Change From Baseline in Patient's Harvey Bradshaw Index (HBI) Total Score to Each Post-Baseline Assessment Month 24	-0.6 units on a scale Standard Deviation 5.1	-0.1 units on a scale Standard Deviation 3.6	-0.8 units on a scale Standard Deviation 4.7	—	—
Change From Baseline in Patient's Harvey Bradshaw Index (HBI) Total Score to Each Post-Baseline Assessment Month 27	-0.6 units on a scale Standard Deviation 4.9	-0.0 units on a scale Standard Deviation 3.6	-0.1 units on a scale Standard Deviation 4.7	—	—
Change From Baseline in Patient's Harvey Bradshaw Index (HBI) Total Score to Each Post-Baseline Assessment Month 30	-0.7 units on a scale Standard Deviation 5.0	-0.1 units on a scale Standard Deviation 3.7	-0.3 units on a scale Standard Deviation 5.3	—	—
Change From Baseline in Patient's Harvey Bradshaw Index (HBI) Total Score to Each Post-Baseline Assessment Month 33	-0.9 units on a scale Standard Deviation 4.8	-0.1 units on a scale Standard Deviation 3.7	-0.3 units on a scale Standard Deviation 5.0	—	—
Change From Baseline in Patient's Harvey Bradshaw Index (HBI) Total Score to Each Post-Baseline Assessment Month 36	-0.6 units on a scale Standard Deviation 5.6	-0.3 units on a scale Standard Deviation 4.0	-0.6 units on a scale Standard Deviation 6.0	—	—
Change From Baseline in Patient's Harvey Bradshaw Index (HBI) Total Score to Each Post-Baseline Assessment Month 39	-0.5 units on a scale Standard Deviation 5.8	-0.3 units on a scale Standard Deviation 3.6	-0.8 units on a scale Standard Deviation 5.3	—	—
Change From Baseline in Patient's Harvey Bradshaw Index (HBI) Total Score to Each Post-Baseline Assessment Month 42	-0.4 units on a scale Standard Deviation 4.8	-0.2 units on a scale Standard Deviation 3.9	-0.8 units on a scale Standard Deviation 5.2	—	—
Change From Baseline in Patient's Harvey Bradshaw Index (HBI) Total Score to Each Post-Baseline Assessment Month 45	-0.5 units on a scale Standard Deviation 4.7	-0.0 units on a scale Standard Deviation 4.1	-1.2 units on a scale Standard Deviation 4.4	—	—
Change From Baseline in Patient's Harvey Bradshaw Index (HBI) Total Score to Each Post-Baseline Assessment Month 48	-0.7 units on a scale Standard Deviation 5.1	-0.0 units on a scale Standard Deviation 4.0	-0.1 units on a scale Standard Deviation 4.7	—	—
Change From Baseline in Patient's Harvey Bradshaw Index (HBI) Total Score to Each Post-Baseline Assessment Month 51	-0.5 units on a scale Standard Deviation 5.0	-0.1 units on a scale Standard Deviation 4.3	-0.8 units on a scale Standard Deviation 5.0	—	—
Change From Baseline in Patient's Harvey Bradshaw Index (HBI) Total Score to Each Post-Baseline Assessment Month 54	-0.6 units on a scale Standard Deviation 4.9	-0.2 units on a scale Standard Deviation 4.0	-0.6 units on a scale Standard Deviation 7.7	—	—
Change From Baseline in Patient's Harvey Bradshaw Index (HBI) Total Score to Each Post-Baseline Assessment Month 57	-1.0 units on a scale Standard Deviation 4.9	-0.2 units on a scale Standard Deviation 3.8	-1.1 units on a scale Standard Deviation 5.9	—	—
Change From Baseline in Patient's Harvey Bradshaw Index (HBI) Total Score to Each Post-Baseline Assessment Month 60	-1.2 units on a scale Standard Deviation 4.8	-0.2 units on a scale Standard Deviation 4.3	-0.6 units on a scale Standard Deviation 6.2	—	—
Change From Baseline in Patient's Harvey Bradshaw Index (HBI) Total Score to Each Post-Baseline Assessment Month 63	-1.2 units on a scale Standard Deviation 4.6	-0.4 units on a scale Standard Deviation 3.8	-0.3 units on a scale Standard Deviation 5.7	—	—
Change From Baseline in Patient's Harvey Bradshaw Index (HBI) Total Score to Each Post-Baseline Assessment Month 66	-1.1 units on a scale Standard Deviation 4.9	-0.2 units on a scale Standard Deviation 4.0	-0.2 units on a scale Standard Deviation 6.7	—	—
Change From Baseline in Patient's Harvey Bradshaw Index (HBI) Total Score to Each Post-Baseline Assessment Month 69	-1.0 units on a scale Standard Deviation 4.7	-0.3 units on a scale Standard Deviation 3.8	-0.7 units on a scale Standard Deviation 5.3	—	—
Change From Baseline in Patient's Harvey Bradshaw Index (HBI) Total Score to Each Post-Baseline Assessment Month 72	-0.8 units on a scale Standard Deviation 5.1	-0.2 units on a scale Standard Deviation 3.9	-1.0 units on a scale Standard Deviation 3.9	—	—
Change From Baseline in Patient's Harvey Bradshaw Index (HBI) Total Score to Each Post-Baseline Assessment Month 75	-0.6 units on a scale Standard Deviation 5.9	-0.1 units on a scale Standard Deviation 4.7	-1.1 units on a scale Standard Deviation 3.6	—	—
Change From Baseline in Patient's Harvey Bradshaw Index (HBI) Total Score to Each Post-Baseline Assessment Month 78	-1.0 units on a scale Standard Deviation 5.1	-0.1 units on a scale Standard Deviation 4.1	-0.6 units on a scale Standard Deviation 4.7	—	—
Change From Baseline in Patient's Harvey Bradshaw Index (HBI) Total Score to Each Post-Baseline Assessment Month 81	-1.1 units on a scale Standard Deviation 5.1	-0.3 units on a scale Standard Deviation 4.0	-0.5 units on a scale Standard Deviation 3.2	—	—
Change From Baseline in Patient's Harvey Bradshaw Index (HBI) Total Score to Each Post-Baseline Assessment Month 84	-1.0 units on a scale Standard Deviation 5.0	-0.3 units on a scale Standard Deviation 4.2	-0.5 units on a scale Standard Deviation 3.0	—	—
Change From Baseline in Patient's Harvey Bradshaw Index (HBI) Total Score to Each Post-Baseline Assessment Month 87	-0.5 units on a scale Standard Deviation 5.4	-0.2 units on a scale Standard Deviation 4.4	-0.5 units on a scale Standard Deviation 3.5	—	—
Change From Baseline in Patient's Harvey Bradshaw Index (HBI) Total Score to Each Post-Baseline Assessment Month 90	-0.7 units on a scale Standard Deviation 5.2	0.0 units on a scale Standard Deviation 4.7	0.3 units on a scale Standard Deviation 5.2	—	—
Change From Baseline in Patient's Harvey Bradshaw Index (HBI) Total Score to Each Post-Baseline Assessment Month 93	-1.3 units on a scale Standard Deviation 5.0	-0.4 units on a scale Standard Deviation 4.3	-0.6 units on a scale Standard Deviation 3.4	—	—
Change From Baseline in Patient's Harvey Bradshaw Index (HBI) Total Score to Each Post-Baseline Assessment Month 96	-1.1 units on a scale Standard Deviation 5.7	-0.5 units on a scale Standard Deviation 4.6	0.3 units on a scale Standard Deviation 3.3	—	—
Change From Baseline in Patient's Harvey Bradshaw Index (HBI) Total Score to Each Post-Baseline Assessment Month 99	-2.2 units on a scale Standard Deviation 6.1	-0.4 units on a scale Standard Deviation 3.9	-0.6 units on a scale Standard Deviation 3.5	—	—
Change From Baseline in Patient's Harvey Bradshaw Index (HBI) Total Score to Each Post-Baseline Assessment Month 102	0.2 units on a scale Standard Deviation 3.3	0.2 units on a scale Standard Deviation 2.4	1.3 units on a scale Standard Deviation 3.7	—	—
Change From Baseline in Patient's Harvey Bradshaw Index (HBI) Total Score to Each Post-Baseline Assessment Month 105	-1.5 units on a scale Standard Deviation 2.1	2.3 units on a scale Standard Deviation 2.3	0.7 units on a scale Standard Deviation 2.6	—	—
Change From Baseline in Patient's Harvey Bradshaw Index (HBI) Total Score to Each Post-Baseline Assessment Month 108	8.0 units on a scale	2.0 units on a scale Standard Deviation 1.7	1.3 units on a scale Standard Deviation 3.0	—	—

SECONDARY outcome

Timeframe: Month 6, 12, 18, 24, 30, 36, 42, 48, 54, 60, 66, 72, 78, 84, 90, 96, 102, and 108, compared to Baseline

Population: Enrolled Set was defined as all participants enrolled and with an informed consent. Here, "Number Analyzed" included those who were evaluable at specified time points only.

Physician assessment of disease severity was measured by the general well-being component of HBI score and had a score range of 0= very well to 4= terrible. Higher scores indicated greater disease activity. A negative change indicated less disease activity.

Outcome measures

Outcome measures
Measure	Cimzia n=1131 Participants Participants (exposure and events) are conservatively included in this group from the time of first administration of Cimzia® until the end of the study even if they switch to comparator. Participants may be included in other treatment groups.	Comparator n=1666 Participants Participants (exposure and events) are included in this group from the time of first administration of comparator until the end of the study or switch to Cimzia®, a participant cannot be in the comparator group if their first treatment in the study was Cimzia®. Participants may be included in other treatment groups.	Overlap n=275 Participants Participants (exposure and events) while receiving Cimzia® along with corticosteroids, immunosuppressants or other biologics (e.g. anti-TNFs) other than Cimzia® including the half-life time of Cimzia® and the comparator. Participants may be included in other treatment groups.	Gap (No Cimzia and no Comparator at Baseline) Participants (exposure and events) neither receiving Cimzia® (including the half-life of Cimzia®) nor receiving comparator (including the half-life). Participants may be included in other treatment groups.	Cimzia + Overlap Participants who received Cimzia® monotherapy or Cimzia® in combination with comparison treatment were included in this group. Participants may be included in other treatment groups.
Change From Baseline in Physician's Assessment of Disease Total Score to Each Post-Baseline Assessment Month 6	-0.4 units on a scale Standard Deviation 0.9	-0.2 units on a scale Standard Deviation 0.8	-0.3 units on a scale Standard Deviation 0.9	—	—
Change From Baseline in Physician's Assessment of Disease Total Score to Each Post-Baseline Assessment Month 12	-0.5 units on a scale Standard Deviation 1.0	-0.3 units on a scale Standard Deviation 0.9	-0.3 units on a scale Standard Deviation 0.9	—	—
Change From Baseline in Physician's Assessment of Disease Total Score to Each Post-Baseline Assessment Month 18	-0.5 units on a scale Standard Deviation 1.0	-0.3 units on a scale Standard Deviation 0.9	-0.3 units on a scale Standard Deviation 0.9	—	—
Change From Baseline in Physician's Assessment of Disease Total Score to Each Post-Baseline Assessment Month 24	-0.6 units on a scale Standard Deviation 1.0	-0.3 units on a scale Standard Deviation 0.9	-0.4 units on a scale Standard Deviation 0.9	—	—
Change From Baseline in Physician's Assessment of Disease Total Score to Each Post-Baseline Assessment Month 30	-0.6 units on a scale Standard Deviation 1.0	-0.3 units on a scale Standard Deviation 0.9	-0.4 units on a scale Standard Deviation 0.9	—	—
Change From Baseline in Physician's Assessment of Disease Total Score to Each Post-Baseline Assessment Month 36	-0.6 units on a scale Standard Deviation 1.0	-0.4 units on a scale Standard Deviation 0.9	-0.5 units on a scale Standard Deviation 0.9	—	—
Change From Baseline in Physician's Assessment of Disease Total Score to Each Post-Baseline Assessment Month 42	-0.6 units on a scale Standard Deviation 1.0	-0.3 units on a scale Standard Deviation 0.9	-0.5 units on a scale Standard Deviation 0.8	—	—
Change From Baseline in Physician's Assessment of Disease Total Score to Each Post-Baseline Assessment Month 48	-0.6 units on a scale Standard Deviation 1.0	-0.3 units on a scale Standard Deviation 0.9	-0.4 units on a scale Standard Deviation 0.9	—	—
Change From Baseline in Physician's Assessment of Disease Total Score to Each Post-Baseline Assessment Month 54	-0.6 units on a scale Standard Deviation 1.0	-0.4 units on a scale Standard Deviation 1.0	-0.4 units on a scale Standard Deviation 1.0	—	—
Change From Baseline in Physician's Assessment of Disease Total Score to Each Post-Baseline Assessment Month 60	-0.7 units on a scale Standard Deviation 1.0	-0.3 units on a scale Standard Deviation 0.9	-0.4 units on a scale Standard Deviation 0.9	—	—
Change From Baseline in Physician's Assessment of Disease Total Score to Each Post-Baseline Assessment Month 66	-0.7 units on a scale Standard Deviation 0.9	-0.3 units on a scale Standard Deviation 0.9	-0.4 units on a scale Standard Deviation 0.8	—	—
Change From Baseline in Physician's Assessment of Disease Total Score to Each Post-Baseline Assessment Month 72	-0.7 units on a scale Standard Deviation 1.0	-0.3 units on a scale Standard Deviation 1.0	-0.4 units on a scale Standard Deviation 0.9	—	—
Change From Baseline in Physician's Assessment of Disease Total Score to Each Post-Baseline Assessment Month 78	-0.7 units on a scale Standard Deviation 0.9	-0.4 units on a scale Standard Deviation 0.9	-0.5 units on a scale Standard Deviation 0.9	—	—
Change From Baseline in Physician's Assessment of Disease Total Score to Each Post-Baseline Assessment Month 84	-0.5 units on a scale Standard Deviation 1.0	-0.4 units on a scale Standard Deviation 0.9	-0.5 units on a scale Standard Deviation 0.8	—	—
Change From Baseline in Physician's Assessment of Disease Total Score to Each Post-Baseline Assessment Month 90	-0.6 units on a scale Standard Deviation 0.9	-0.4 units on a scale Standard Deviation 0.9	-0.7 units on a scale Standard Deviation 0.8	—	—
Change From Baseline in Physician's Assessment of Disease Total Score to Each Post-Baseline Assessment Month 96	-0.6 units on a scale Standard Deviation 1.0	-0.3 units on a scale Standard Deviation 0.9	-0.4 units on a scale Standard Deviation 1.0	—	—
Change From Baseline in Physician's Assessment of Disease Total Score to Each Post-Baseline Assessment Month 102	-0.4 units on a scale Standard Deviation 1.1	-0.4 units on a scale Standard Deviation 1.1	-0.1 units on a scale Standard Deviation 0.8	—	—
Change From Baseline in Physician's Assessment of Disease Total Score to Each Post-Baseline Assessment Month 108	-0.3 units on a scale Standard Deviation 1.0	-0.1 units on a scale Standard Deviation 1.1	-0.3 units on a scale Standard Deviation 0.5	—	—

SECONDARY outcome

Timeframe: Month 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75, 78, 81, 84, 87, 90, 93, 96, 99, 102, 105 and 108, compared to Baseline

Population: Enrolled Set was defined as all participants enrolled and with an informed consent. Here, "Number Analyzed" included those who were evaluable at specified time points only.

Patient assessment of disease severity was measured by the general well-being component of HBI score and had a score range of 0= very well to 4= terrible. Higher scores indicated greater disease activity. A negative change indicated less disease activity.

Outcome measures

Outcome measures
Measure	Cimzia n=1131 Participants Participants (exposure and events) are conservatively included in this group from the time of first administration of Cimzia® until the end of the study even if they switch to comparator. Participants may be included in other treatment groups.	Comparator n=1666 Participants Participants (exposure and events) are included in this group from the time of first administration of comparator until the end of the study or switch to Cimzia®, a participant cannot be in the comparator group if their first treatment in the study was Cimzia®. Participants may be included in other treatment groups.	Overlap n=275 Participants Participants (exposure and events) while receiving Cimzia® along with corticosteroids, immunosuppressants or other biologics (e.g. anti-TNFs) other than Cimzia® including the half-life time of Cimzia® and the comparator. Participants may be included in other treatment groups.	Gap (No Cimzia and no Comparator at Baseline) Participants (exposure and events) neither receiving Cimzia® (including the half-life of Cimzia®) nor receiving comparator (including the half-life). Participants may be included in other treatment groups.	Cimzia + Overlap Participants who received Cimzia® monotherapy or Cimzia® in combination with comparison treatment were included in this group. Participants may be included in other treatment groups.
Change From Baseline in Patient's Assessment of Disease Total Score to Each Post-Baseline Assessment Month 102	0.1 units on a scale Standard Deviation 0.9	0.2 units on a scale Standard Deviation 0.7	0.0 units on a scale Standard Deviation 0.6	—	—
Change From Baseline in Patient's Assessment of Disease Total Score to Each Post-Baseline Assessment Month 18	-0.3 units on a scale Standard Deviation 0.9	-0.2 units on a scale Standard Deviation 0.9	-0.2 units on a scale Standard Deviation 0.8	—	—
Change From Baseline in Patient's Assessment of Disease Total Score to Each Post-Baseline Assessment Month 84	-0.5 units on a scale Standard Deviation 0.9	-0.3 units on a scale Standard Deviation 0.9	-0.3 units on a scale Standard Deviation 0.9	—	—
Change From Baseline in Patient's Assessment of Disease Total Score to Each Post-Baseline Assessment Month 87	-0.4 units on a scale Standard Deviation 0.9	-0.2 units on a scale Standard Deviation 0.9	-0.2 units on a scale Standard Deviation 0.8	—	—
Change From Baseline in Patient's Assessment of Disease Total Score to Each Post-Baseline Assessment Month 90	-0.4 units on a scale Standard Deviation 0.9	-0.2 units on a scale Standard Deviation 0.9	-0.3 units on a scale Standard Deviation 0.8	—	—
Change From Baseline in Patient's Assessment of Disease Total Score to Each Post-Baseline Assessment Month 93	-0.4 units on a scale Standard Deviation 0.9	-0.2 units on a scale Standard Deviation 0.9	-0.2 units on a scale Standard Deviation 1.0	—	—
Change From Baseline in Patient's Assessment of Disease Total Score to Each Post-Baseline Assessment Month 96	-0.5 units on a scale Standard Deviation 0.9	-0.2 units on a scale Standard Deviation 0.9	0.0 units on a scale Standard Deviation 0.9	—	—
Change From Baseline in Patient's Assessment of Disease Total Score to Each Post-Baseline Assessment Month 99	-0.5 units on a scale Standard Deviation 0.9	-0.2 units on a scale Standard Deviation 0.8	0.1 units on a scale Standard Deviation 0.8	—	—
Change From Baseline in Patient's Assessment of Disease Total Score to Each Post-Baseline Assessment Month 3	-0.0 units on a scale Standard Deviation 0.8	-0.0 units on a scale Standard Deviation 0.7	-0.1 units on a scale Standard Deviation 0.9	—	—
Change From Baseline in Patient's Assessment of Disease Total Score to Each Post-Baseline Assessment Month 6	-0.2 units on a scale Standard Deviation 0.9	-0.1 units on a scale Standard Deviation 0.8	-0.1 units on a scale Standard Deviation 0.8	—	—
Change From Baseline in Patient's Assessment of Disease Total Score to Each Post-Baseline Assessment Month 9	-0.2 units on a scale Standard Deviation 0.9	-0.1 units on a scale Standard Deviation 0.9	-0.3 units on a scale Standard Deviation 0.9	—	—
Change From Baseline in Patient's Assessment of Disease Total Score to Each Post-Baseline Assessment Month 12	-0.2 units on a scale Standard Deviation 0.9	-0.1 units on a scale Standard Deviation 0.8	-0.2 units on a scale Standard Deviation 0.8	—	—
Change From Baseline in Patient's Assessment of Disease Total Score to Each Post-Baseline Assessment Month 15	-0.3 units on a scale Standard Deviation 0.9	-0.1 units on a scale Standard Deviation 0.8	-0.2 units on a scale Standard Deviation 0.9	—	—
Change From Baseline in Patient's Assessment of Disease Total Score to Each Post-Baseline Assessment Month 21	-0.3 units on a scale Standard Deviation 0.9	-0.2 units on a scale Standard Deviation 0.8	-0.3 units on a scale Standard Deviation 1.0	—	—
Change From Baseline in Patient's Assessment of Disease Total Score to Each Post-Baseline Assessment Month 24	-0.3 units on a scale Standard Deviation 1.0	-0.2 units on a scale Standard Deviation 0.9	-0.3 units on a scale Standard Deviation 1.0	—	—
Change From Baseline in Patient's Assessment of Disease Total Score to Each Post-Baseline Assessment Month 27	-0.3 units on a scale Standard Deviation 1.0	-0.2 units on a scale Standard Deviation 0.8	-0.4 units on a scale Standard Deviation 0.9	—	—
Change From Baseline in Patient's Assessment of Disease Total Score to Each Post-Baseline Assessment Month 30	-0.3 units on a scale Standard Deviation 1.0	-0.2 units on a scale Standard Deviation 0.8	-0.4 units on a scale Standard Deviation 0.9	—	—
Change From Baseline in Patient's Assessment of Disease Total Score to Each Post-Baseline Assessment Month 33	-0.4 units on a scale Standard Deviation 1.0	-0.2 units on a scale Standard Deviation 0.9	-0.3 units on a scale Standard Deviation 0.9	—	—
Change From Baseline in Patient's Assessment of Disease Total Score to Each Post-Baseline Assessment Month 36	-0.4 units on a scale Standard Deviation 1.0	-0.2 units on a scale Standard Deviation 0.9	-0.4 units on a scale Standard Deviation 0.9	—	—
Change From Baseline in Patient's Assessment of Disease Total Score to Each Post-Baseline Assessment Month 39	-0.3 units on a scale Standard Deviation 1.0	-0.2 units on a scale Standard Deviation 0.9	-0.3 units on a scale Standard Deviation 1.1	—	—
Change From Baseline in Patient's Assessment of Disease Total Score to Each Post-Baseline Assessment Month 42	-0.4 units on a scale Standard Deviation 1.0	-0.2 units on a scale Standard Deviation 0.9	-0.4 units on a scale Standard Deviation 0.9	—	—
Change From Baseline in Patient's Assessment of Disease Total Score to Each Post-Baseline Assessment Month 45	-0.3 units on a scale Standard Deviation 1.0	-0.1 units on a scale Standard Deviation 0.8	-0.6 units on a scale Standard Deviation 0.8	—	—
Change From Baseline in Patient's Assessment of Disease Total Score to Each Post-Baseline Assessment Month 48	-0.4 units on a scale Standard Deviation 1.0	-0.2 units on a scale Standard Deviation 0.8	-0.3 units on a scale Standard Deviation 0.9	—	—
Change From Baseline in Patient's Assessment of Disease Total Score to Each Post-Baseline Assessment Month 51	-0.4 units on a scale Standard Deviation 1.0	-0.2 units on a scale Standard Deviation 0.8	-0.3 units on a scale Standard Deviation 0.9	—	—
Change From Baseline in Patient's Assessment of Disease Total Score to Each Post-Baseline Assessment Month 54	-0.4 units on a scale Standard Deviation 1.0	-0.2 units on a scale Standard Deviation 0.9	-0.2 units on a scale Standard Deviation 1.0	—	—
Change From Baseline in Patient's Assessment of Disease Total Score to Each Post-Baseline Assessment Month 57	-0.4 units on a scale Standard Deviation 1.0	-0.2 units on a scale Standard Deviation 0.8	-0.4 units on a scale Standard Deviation 0.9	—	—
Change From Baseline in Patient's Assessment of Disease Total Score to Each Post-Baseline Assessment Month 60	-0.5 units on a scale Standard Deviation 1.0	-0.3 units on a scale Standard Deviation 0.9	-0.3 units on a scale Standard Deviation 0.9	—	—
Change From Baseline in Patient's Assessment of Disease Total Score to Each Post-Baseline Assessment Month 63	-0.5 units on a scale Standard Deviation 1.0	-0.2 units on a scale Standard Deviation 0.9	-0.1 units on a scale Standard Deviation 1.0	—	—
Change From Baseline in Patient's Assessment of Disease Total Score to Each Post-Baseline Assessment Month 66	-0.5 units on a scale Standard Deviation 0.9	-0.2 units on a scale Standard Deviation 0.8	-0.3 units on a scale Standard Deviation 0.9	—	—
Change From Baseline in Patient's Assessment of Disease Total Score to Each Post-Baseline Assessment Month 69	-0.5 units on a scale Standard Deviation 1.0	-0.2 units on a scale Standard Deviation 0.9	-0.3 units on a scale Standard Deviation 0.9	—	—
Change From Baseline in Patient's Assessment of Disease Total Score to Each Post-Baseline Assessment Month 72	-0.5 units on a scale Standard Deviation 0.9	-0.2 units on a scale Standard Deviation 0.9	-0.4 units on a scale Standard Deviation 0.8	—	—
Change From Baseline in Patient's Assessment of Disease Total Score to Each Post-Baseline Assessment Month 75	-0.4 units on a scale Standard Deviation 0.9	-0.2 units on a scale Standard Deviation 0.9	-0.4 units on a scale Standard Deviation 0.9	—	—
Change From Baseline in Patient's Assessment of Disease Total Score to Each Post-Baseline Assessment Month 78	-0.4 units on a scale Standard Deviation 0.9	-0.2 units on a scale Standard Deviation 0.9	-0.3 units on a scale Standard Deviation 0.9	—	—
Change From Baseline in Patient's Assessment of Disease Total Score to Each Post-Baseline Assessment Month 81	-0.5 units on a scale Standard Deviation 0.9	-0.3 units on a scale Standard Deviation 0.9	-0.2 units on a scale Standard Deviation 0.9	—	—
Change From Baseline in Patient's Assessment of Disease Total Score to Each Post-Baseline Assessment Month 105	0.5 units on a scale Standard Deviation 0.7	0.3 units on a scale Standard Deviation 0.6	0.3 units on a scale Standard Deviation 0.5	—	—
Change From Baseline in Patient's Assessment of Disease Total Score to Each Post-Baseline Assessment Month 108	1.0 units on a scale	0.3 units on a scale Standard Deviation 0.6	0.4 units on a scale Standard Deviation 0.5	—	—

Adverse Events

Cimzia

Serious events: 145 serious events

Other events: 19 other events

Deaths: 3 deaths

Comparator

Serious events: 638 serious events

Other events: 70 other events

Deaths: 25 deaths

Overlap

Serious events: 268 serious events

Other events: 30 other events

Deaths: 6 deaths

Gap (No Cimzia and no Comparator at Baseline)

Serious events: 152 serious events

Other events: 9 other events

Deaths: 17 deaths

Cimzia + Overlap

Serious events: 385 serious events

Other events: 48 other events

Deaths: 9 deaths

Serious adverse events

Serious adverse events
Measure	Cimzia n=824 participants at risk Participants (exposure and events) while receiving Cimzia® only including the half-life of Cimzia® without comparator including half-life of comparator. Participants may be included in treatment groups.	Comparator n=2478 participants at risk Participants (exposure and events) while receiving corticosteroids, immunosuppressants or other biologics (e.g. anti-TNFs) other than Cimzia®, alone or in combination with each other including their half-life. Participants may be included in other treatment groups.	Overlap n=1165 participants at risk Participants (exposure and events) while receiving Cimzia® along with corticosteroids, immunosuppressants or other biologics (e.g. anti-TNFs) other than Cimzia® including the half-life time of Cimzia® and the comparator. Participants may be included in other treatment groups.	Gap (No Cimzia and no Comparator at Baseline) n=1022 participants at risk Participants (exposure and events) neither receiving Cimzia® (including the half-life of Cimzia®) nor receiving comparator (including the half-life).	Cimzia + Overlap n=1428 participants at risk Participants who received Cimzia® monotherapy or Cimzia® in combination with comparison treatment were included in this group. Participants may be included in other treatment groups.
Gastrointestinal disorders Duodenal ulcer haemorrhage	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Blood and lymphatic system disorders Iron deficiency anaemia	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.14% 2/1428 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Blood and lymphatic system disorders Anaemia	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.20% 5/2478 • Number of events 5 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.26% 3/1165 • Number of events 3 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.20% 2/1022 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.21% 3/1428 • Number of events 3 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Blood and lymphatic system disorders Haemorrhagic anaemia	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Blood and lymphatic system disorders Autoimmune haemolytic anaemia	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Blood and lymphatic system disorders Haemolytic uraemic syndrome	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Blood and lymphatic system disorders Bone marrow failure	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Blood and lymphatic system disorders Pancytopenia	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Cardiac disorders Aortic valve disease	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Cardiac disorders Palpitations	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Cardiac disorders Cardiac disorder	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Cardiac disorders Congestive cardiomyopathy	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Cardiac disorders Ischaemic cardiomyopathy	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Cardiac disorders Coronary artery occlusion	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Cardiac disorders Coronary artery disease	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Cardiac disorders Cardiac failure congestive	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.08% 2/2478 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Cardiac disorders Acute myocardial infarction	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.26% 3/1165 • Number of events 3 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.28% 4/1428 • Number of events 4 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Cardiac disorders Angina pectoris	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Cardiac disorders Acute coronary syndrome	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Cardiac disorders Myocardial infarction	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.08% 2/2478 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Cardiac disorders Acute left ventricular failure	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Cardiac disorders Pericarditis	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.08% 2/2478 • Number of events 3 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Cardiac disorders Pericardial effusion	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.08% 2/2478 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Cardiac disorders Bradycardia	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Cardiac disorders Tachycardia	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Cardiac disorders Atrial fibrillation	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.20% 2/1022 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.14% 2/1428 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Cardiac disorders Atrial flutter	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Cardiac disorders Supraventricular tachycardia	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Cardiac disorders Cardiac arrest	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.20% 2/1022 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Congenital, familial and genetic disorders Intestinal malrotation	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Congenital, familial and genetic disorders Micrognathia	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Congenital, familial and genetic disorders Persistent urogenital sinus	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Congenital, familial and genetic disorders Ankyloglossia congenital	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Endocrine disorders Adrenal insufficiency	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Endocrine disorders Inappropriate antidiuretic hormone secretion	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Endocrine disorders Hypothyroidism	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Eye disorders Exophthalmos	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Eye disorders Visual impairment	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Gastrointestinal disorders Abdominal mass	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Gastrointestinal disorders Abdominal hernia	0.49% 4/824 • Number of events 4 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.08% 2/2478 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.28% 4/1428 • Number of events 4 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Gastrointestinal disorders Abdominal incarcerated hernia	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Gastrointestinal disorders Internal hernia	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Gastrointestinal disorders Abdominal wall mass	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Gastrointestinal disorders Pancreatitis acute	0.36% 3/824 • Number of events 3 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.20% 5/2478 • Number of events 6 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.17% 2/1165 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.35% 5/1428 • Number of events 5 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Gastrointestinal disorders Pancreatitis	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.32% 8/2478 • Number of events 8 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.14% 2/1428 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Gastrointestinal disorders Pancreatitis haemorrhagic	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Gastrointestinal disorders Pancreatitis chronic	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Gastrointestinal disorders Anal skin tags	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Gastrointestinal disorders Rectal fissure	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Gastrointestinal disorders Anal fissure	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Gastrointestinal disorders Rectal prolapse	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Gastrointestinal disorders Proctalgia	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.26% 3/1165 • Number of events 3 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.21% 3/1428 • Number of events 3 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Gastrointestinal disorders Anal stenosis	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.12% 3/2478 • Number of events 3 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.14% 2/1428 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Gastrointestinal disorders Rectal perforation	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Gastrointestinal disorders Crohn's disease	2.9% 24/824 • Number of events 27 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	7.7% 192/2478 • Number of events 276 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	8.7% 101/1165 • Number of events 143 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	3.9% 40/1022 • Number of events 45 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	8.6% 123/1428 • Number of events 170 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Gastrointestinal disorders Colitis	0.24% 2/824 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.12% 3/2478 • Number of events 3 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.14% 2/1428 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Gastrointestinal disorders Colitis ischaemic	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Gastrointestinal disorders Colitis ulcerative	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.08% 2/2478 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Gastrointestinal disorders Inflammatory bowel disease	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.08% 2/2478 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Gastrointestinal disorders Diarrhoea	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.24% 6/2478 • Number of events 6 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.20% 2/1022 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Gastrointestinal disorders Diarrhoea haemorrhagic	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.17% 2/1165 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.14% 2/1428 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Gastrointestinal disorders Small intestinal obstruction	2.8% 23/824 • Number of events 27 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	3.8% 93/2478 • Number of events 123 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	2.0% 23/1165 • Number of events 33 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	1.8% 18/1022 • Number of events 26 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	3.2% 45/1428 • Number of events 60 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Gastrointestinal disorders Small intestinal stenosis	0.73% 6/824 • Number of events 6 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.20% 5/2478 • Number of events 6 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.49% 7/1428 • Number of events 7 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Gastrointestinal disorders Ileal stenosis	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.20% 5/2478 • Number of events 5 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.26% 3/1165 • Number of events 3 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.28% 4/1428 • Number of events 4 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Gastrointestinal disorders Duodenal obstruction	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Gastrointestinal disorders Duodenal ulcer	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Gastrointestinal disorders Faecaloma	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Gastrointestinal disorders Abdominal distension	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Gastrointestinal disorders Obstruction gastric	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Gastrointestinal disorders Gastric perforation	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Gastrointestinal disorders Gastroduodenitis	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Gastrointestinal disorders Gastritis	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Gastrointestinal disorders Abdominal pain	0.24% 2/824 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	1.1% 28/2478 • Number of events 37 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	1.5% 17/1165 • Number of events 20 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.39% 4/1022 • Number of events 4 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	1.3% 19/1428 • Number of events 22 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Gastrointestinal disorders Abdominal pain lower	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.08% 2/2478 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.14% 2/1428 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Gastrointestinal disorders Abdominal pain upper	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.12% 3/2478 • Number of events 4 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Gastrointestinal disorders Impaired gastric emptying	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Gastrointestinal disorders Gastrointestinal hypomotility	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Gastrointestinal disorders Gastrooesophageal reflux disease	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Gastrointestinal disorders Intestinal dilatation	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Gastrointestinal disorders Pneumatosis intestinalis	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Gastrointestinal disorders Food poisoning	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Gastrointestinal disorders Anal fistula	0.24% 2/824 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.16% 4/2478 • Number of events 4 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.34% 4/1165 • Number of events 5 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.42% 6/1428 • Number of events 7 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Gastrointestinal disorders Enterocutaneous fistula	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.16% 4/2478 • Number of events 4 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.26% 3/1165 • Number of events 3 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.28% 4/1428 • Number of events 4 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Gastrointestinal disorders Fistula of small intestine	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Gastrointestinal disorders Intestinal fistula	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.08% 2/2478 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Gastrointestinal disorders Enterovesical fistula	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.17% 2/1165 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.14% 2/1428 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Gastrointestinal disorders Enteritis	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Gastrointestinal disorders Enterocolitis	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.20% 2/1022 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Gastrointestinal disorders Pouchitis	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Gastrointestinal disorders Abdominal discomfort	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Gastrointestinal disorders Dysphagia	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Gastrointestinal disorders Irritable bowel syndrome	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.08% 2/2478 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Gastrointestinal disorders Intestinal obstruction	0.36% 3/824 • Number of events 4 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.97% 24/2478 • Number of events 26 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.77% 9/1165 • Number of events 9 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.49% 5/1022 • Number of events 5 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.84% 12/1428 • Number of events 13 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Gastrointestinal disorders Ileus	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.12% 3/2478 • Number of events 3 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.34% 4/1165 • Number of events 4 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.35% 5/1428 • Number of events 5 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Gastrointestinal disorders Intestinal stenosis	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.61% 15/2478 • Number of events 15 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.60% 7/1165 • Number of events 7 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.56% 8/1428 • Number of events 8 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Gastrointestinal disorders Intussusception	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Gastrointestinal disorders Coeliac artery compression syndrome	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Gastrointestinal disorders Haemorrhoids	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Gastrointestinal disorders Haemorrhoidal haemorrhage	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Gastrointestinal disorders Inguinal hernia	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Gastrointestinal disorders Rectal haemorrhage	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.12% 3/2478 • Number of events 3 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Gastrointestinal disorders Small intestinal haemorrhage	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.08% 2/2478 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Gastrointestinal disorders Intestinal perforation	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.08% 2/2478 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.29% 3/1022 • Number of events 3 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.14% 2/1428 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Gastrointestinal disorders Ileal perforation	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Gastrointestinal disorders Jejunal ulcer	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Gastrointestinal disorders Large intestine perforation	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.16% 4/2478 • Number of events 4 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.17% 2/1165 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.14% 2/1428 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Gastrointestinal disorders Small intestinal perforation	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Gastrointestinal disorders Large intestinal obstruction	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.12% 3/2478 • Number of events 4 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.20% 2/1022 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Gastrointestinal disorders Large intestinal stenosis	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.20% 5/2478 • Number of events 5 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.26% 3/1165 • Number of events 3 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.21% 3/1428 • Number of events 3 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Gastrointestinal disorders Malabsorption	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Gastrointestinal disorders Nausea	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.20% 5/2478 • Number of events 5 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.17% 2/1165 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.14% 2/1428 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Gastrointestinal disorders Vomiting	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.24% 6/2478 • Number of events 7 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Gastrointestinal disorders Ileus paralytic	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Gastrointestinal disorders Gastrointestinal haemorrhage	0.24% 2/824 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.16% 4/2478 • Number of events 4 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.17% 2/1165 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.28% 4/1428 • Number of events 4 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Gastrointestinal disorders Haematemesis	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Gastrointestinal disorders Haematochezia	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Gastrointestinal disorders Lower gastrointestinal haemorrhage	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.08% 2/2478 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Gastrointestinal disorders Upper gastrointestinal haemorrhage	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Gastrointestinal disorders Oesophageal perforation	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Gastrointestinal disorders Pancreatic failure	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Gastrointestinal disorders Peptic ulcer	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Gastrointestinal disorders Intra-abdominal fluid collection	0.24% 2/824 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.08% 2/2478 • Number of events 3 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.21% 3/1428 • Number of events 3 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Gastrointestinal disorders Pneumoperitoneum	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Gastrointestinal disorders Abdominal adhesions	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Gastrointestinal disorders Proctitis	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Gastrointestinal disorders Stomatitis	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Gastrointestinal disorders Umbilical hernia	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.17% 2/1165 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.14% 2/1428 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
General disorders Asthenia	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
General disorders Complication associated with device	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
General disorders Death	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.12% 3/2478 • Number of events 3 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.20% 2/1022 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.14% 2/1428 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
General disorders Pyrexia	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.24% 6/2478 • Number of events 6 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.17% 2/1165 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.14% 2/1428 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
General disorders Adhesion	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
General disorders Influenza like illness	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
General disorders Multiple organ dysfunction syndrome	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
General disorders Obstruction	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
General disorders Hernia	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
General disorders Incarcerated hernia	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
General disorders Systemic inflammatory response syndrome	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.08% 2/2478 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
General disorders Food interaction	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
General disorders Cyst	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
General disorders Mucosal inflammation	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
General disorders Oedema peripheral	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
General disorders Non-cardiac chest pain	0.24% 2/824 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.12% 3/2478 • Number of events 3 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.17% 2/1165 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.20% 2/1022 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.28% 4/1428 • Number of events 4 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
General disorders Chest pain	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.08% 2/2478 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
General disorders Pain	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.20% 2/1022 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
General disorders Device related thrombosis	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Hepatobiliary disorders Cholangitis	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Hepatobiliary disorders Cholecystitis acute	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.12% 3/2478 • Number of events 3 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Hepatobiliary disorders Cholelithiasis	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.12% 3/2478 • Number of events 3 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.17% 2/1165 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.21% 3/1428 • Number of events 3 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Hepatobiliary disorders Cholecystitis	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.17% 2/1165 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.14% 2/1428 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Hepatobiliary disorders Hepatitis cholestatic	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Hepatobiliary disorders Biliary dyskinesia	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Hepatobiliary disorders Gallbladder polyp	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.08% 2/2478 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Hepatobiliary disorders Hepatic vein thrombosis	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Hepatobiliary disorders Portal vein thrombosis	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.08% 2/2478 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.20% 2/1022 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Hepatobiliary disorders Hepatitis acute	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Hepatobiliary disorders Drug-induced liver injury	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Hepatobiliary disorders Hepatitis alcoholic	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.08% 2/2478 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Immune system disorders Hypersensitivity	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Immune system disorders Drug hypersensitivity	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.16% 4/2478 • Number of events 4 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Immune system disorders Anaphylactic reaction	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.17% 2/1165 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.14% 2/1428 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Abdominal abscess	0.61% 5/824 • Number of events 5 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.56% 14/2478 • Number of events 21 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.94% 11/1165 • Number of events 11 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	1.1% 16/1428 • Number of events 16 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Anal abscess	0.49% 4/824 • Number of events 4 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.24% 6/2478 • Number of events 8 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.35% 5/1428 • Number of events 5 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Gastroenteritis	0.24% 2/824 • Number of events 3 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.12% 3/2478 • Number of events 3 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.17% 2/1165 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.20% 2/1022 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.28% 4/1428 • Number of events 5 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Perirectal abscess	0.24% 2/824 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.36% 9/2478 • Number of events 10 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.52% 6/1165 • Number of events 6 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.29% 3/1022 • Number of events 3 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.56% 8/1428 • Number of events 8 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Abdominal infection	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.08% 2/2478 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Abdominal wall abscess	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.12% 3/2478 • Number of events 3 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.14% 2/1428 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Abscess intestinal	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.08% 2/2478 • Number of events 3 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Anal fistula infection	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.08% 2/2478 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Appendicitis	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.20% 5/2478 • Number of events 5 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Appendicitis perforated	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Colonic abscess	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Diarrhoea infectious	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Diverticulitis	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.17% 2/1165 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.20% 2/1022 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.14% 2/1428 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Gastrointestinal infection	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Intestinal fistula infection	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Peritoneal abscess	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Peritonitis	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Rectal abscess	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.20% 5/2478 • Number of events 5 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Retroperitoneal abscess	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Mycobacterium chelonae infection	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Mycobacterium kansasii infection	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Cellulitis	0.24% 2/824 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.32% 8/2478 • Number of events 9 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.77% 9/1165 • Number of events 9 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.77% 11/1428 • Number of events 11 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Anorectal cellulitis	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Bacterial sepsis	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Stoma site cellulitis	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Urinary tract infection bacterial	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Bursitis infective	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Osteomyelitis	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Pertussis	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Gastroenteritis norovirus	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Campylobacter infection	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Candida infection	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Oesophageal candidiasis	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.08% 2/2478 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Oropharyngeal candidiasis	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Systemic candida	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Meningitis aseptic	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Clostridium difficile infection	0.24% 2/824 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.36% 9/2478 • Number of events 9 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.43% 5/1165 • Number of events 5 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.49% 5/1022 • Number of events 5 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.49% 7/1428 • Number of events 7 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Clostridium difficile colitis	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.20% 5/2478 • Number of events 5 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.26% 3/1165 • Number of events 3 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.21% 3/1428 • Number of events 3 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Cytomegalovirus infection	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Tooth abscess	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Tooth infection	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Otitis media	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Otitis media acute	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Enterovirus infection	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Epstein-Barr virus infection	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Escherichia bacteraemia	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Conjunctivitis	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Pelvic inflammatory disease	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Giardiasis	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Liver abscess	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Genital herpes	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Herpes zoster	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.26% 3/1165 • Number of events 3 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.21% 3/1428 • Number of events 3 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Oral herpes	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Device related infection	0.24% 2/824 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.08% 2/2478 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.21% 3/1428 • Number of events 3 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Pelvic abscess	0.24% 2/824 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.17% 2/1165 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.28% 4/1428 • Number of events 4 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Abscess	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.24% 6/2478 • Number of events 6 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Incision site abscess	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Infection	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Postoperative wound infection	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.08% 2/2478 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.26% 3/1165 • Number of events 3 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.28% 4/1428 • Number of events 4 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Wound infection	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Groin abscess	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Incision site infection	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Infected fistula	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.08% 2/2478 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Localised infection	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Medical device site infection	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Pathogen resistance	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Post procedural infection	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Stoma site abscess	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Influenza	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.12% 3/2478 • Number of events 3 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.17% 2/1165 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.21% 3/1428 • Number of events 3 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Pneumonia legionella	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Listeria sepsis	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Pneumonia	0.24% 2/824 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.97% 24/2478 • Number of events 25 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.86% 10/1165 • Number of events 10 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.39% 4/1022 • Number of events 4 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.84% 12/1428 • Number of events 12 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Bronchitis	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.12% 3/2478 • Number of events 3 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Infectious pleural effusion	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Atypical pneumonia	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Lung abscess	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Scrotal abscess	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Muscle abscess	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Psoas abscess	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Soft tissue infection	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Parainfluenzae virus infection	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Sepsis	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.44% 11/2478 • Number of events 14 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.52% 6/1165 • Number of events 6 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.39% 4/1022 • Number of events 4 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.49% 7/1428 • Number of events 7 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Abdominal sepsis	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Bacteraemia	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.08% 2/2478 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Device related sepsis	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.12% 3/2478 • Number of events 4 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Fungaemia	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Neutropenic sepsis	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Septic shock	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.16% 4/2478 • Number of events 4 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Urosepsis	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.08% 2/2478 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.17% 2/1165 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.14% 2/1428 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Shigella infection	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Subcutaneous abscess	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Carbuncle	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Pyoderma	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Staphylococcal abscess	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Staphylococcal bacteraemia	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.20% 2/1022 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.14% 2/1428 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Staphylococcal sepsis	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Cellulitis staphylococcal	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Endocarditis staphylococcal	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Staphylococcal infection	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Wound infection staphylococcal	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Erysipelas	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Pharyngitis streptococcal	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Chronic tonsillitis	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Urinary tract infection	0.24% 2/824 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.32% 8/2478 • Number of events 8 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.34% 4/1165 • Number of events 5 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.20% 2/1022 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.42% 6/1428 • Number of events 7 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Kidney infection	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Cystitis	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Pyelonephritis	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.16% 4/2478 • Number of events 4 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Pyelonephritis acute	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Ureteritis	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Urinary bladder abscess	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Infusion site infection	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Gastroenteritis viral	0.24% 2/824 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.16% 4/2478 • Number of events 4 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.43% 5/1165 • Number of events 5 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.49% 7/1428 • Number of events 7 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Viral infection	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Gastrointestinal viral infection	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Injury, poisoning and procedural complications Subarachnoid haemorrhage	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Injury, poisoning and procedural complications Traumatic intracranial haemorrhage	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Injury, poisoning and procedural complications Procedural intestinal perforation	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Injury, poisoning and procedural complications Abdominal wound dehiscence	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Injury, poisoning and procedural complications Gastrointestinal anastomotic stenosis	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Injury, poisoning and procedural complications Intestinal anastomosis complication	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Injury, poisoning and procedural complications Postoperative ileus	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.08% 2/2478 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Injury, poisoning and procedural complications Procedural nausea	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Injury, poisoning and procedural complications Heat illness	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Injury, poisoning and procedural complications Femur fracture	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 3 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.14% 2/1428 • Number of events 4 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Injury, poisoning and procedural complications Hip fracture	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.08% 2/2478 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Injury, poisoning and procedural complications Tibia fracture	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Injury, poisoning and procedural complications Ulna fracture	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Injury, poisoning and procedural complications Tendon rupture	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Injury, poisoning and procedural complications Periprosthetic fracture	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Injury, poisoning and procedural complications Pneumocephalus	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Injury, poisoning and procedural complications Post lumbar puncture syndrome	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Injury, poisoning and procedural complications Arthropod bite	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Injury, poisoning and procedural complications Road traffic accident	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Injury, poisoning and procedural complications Incision site pain	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Injury, poisoning and procedural complications Anastomotic complication	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Injury, poisoning and procedural complications Anastomotic leak	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Injury, poisoning and procedural complications Anastomotic stenosis	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Injury, poisoning and procedural complications Incarcerated incisional hernia	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Injury, poisoning and procedural complications Incisional hernia	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.08% 2/2478 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.17% 2/1165 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.14% 2/1428 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Injury, poisoning and procedural complications Post procedural haemorrhage	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Injury, poisoning and procedural complications Postoperative fever	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Injury, poisoning and procedural complications Procedural hypotension	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Injury, poisoning and procedural complications Procedural pain	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.12% 3/2478 • Number of events 3 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.17% 2/1165 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.14% 2/1428 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Injury, poisoning and procedural complications Wound dehiscence	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.12% 3/2478 • Number of events 3 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Injury, poisoning and procedural complications Intentional overdose	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Injury, poisoning and procedural complications Overdose	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.17% 2/1165 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.14% 2/1428 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Injury, poisoning and procedural complications Acetabulum fracture	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Injury, poisoning and procedural complications Alcohol poisoning	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Injury, poisoning and procedural complications Toxicity to various agents	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.12% 3/2478 • Number of events 3 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Injury, poisoning and procedural complications Ureteric injury	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Injury, poisoning and procedural complications Uterine rupture	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Injury, poisoning and procedural complications Head injury	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Injury, poisoning and procedural complications Spinal compression fracture	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Injury, poisoning and procedural complications Gastrointestinal stoma complication	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.12% 3/2478 • Number of events 3 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.26% 3/1165 • Number of events 3 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.39% 4/1022 • Number of events 4 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.21% 3/1428 • Number of events 3 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Injury, poisoning and procedural complications Stoma site ulcer	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Injury, poisoning and procedural complications Stomal hernia	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.24% 6/2478 • Number of events 10 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.20% 2/1022 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Injury, poisoning and procedural complications Burns second degree	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Injury, poisoning and procedural complications Thermal burn	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Injury, poisoning and procedural complications Rib fracture	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.08% 2/2478 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Investigations Cardiac stress test abnormal	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Investigations White blood cells stool positive	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Investigations Gastrointestinal stoma output decreased	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Investigations Liver function test increased	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Investigations Transaminases increased	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Investigations Weight decreased	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Investigations Rectal examination	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Investigations Blood creatinine increased	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Investigations Norovirus test positive	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.08% 2/2478 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Investigations White blood cell count increased	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Metabolism and nutrition disorders Appetite disorders	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Metabolism and nutrition disorders Decreased appetite	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Metabolism and nutrition disorders Hypocalcaemia	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Metabolism and nutrition disorders Hypercalcaemia	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Metabolism and nutrition disorders Diabetes mellitus	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Metabolism and nutrition disorders Type 2 diabetes mellitus	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Metabolism and nutrition disorders Diabetic ketoacidosis	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Metabolism and nutrition disorders Electrolyte imbalance	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.08% 2/2478 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 5 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Metabolism and nutrition disorders Electrolyte depletion	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Metabolism and nutrition disorders Malnutrition	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.20% 5/2478 • Number of events 5 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.17% 2/1165 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.21% 3/1428 • Number of events 3 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Metabolism and nutrition disorders Weight gain poor	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Metabolism and nutrition disorders Failure to thrive	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.28% 7/2478 • Number of events 7 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Metabolism and nutrition disorders Obesity	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Metabolism and nutrition disorders Hypoglycaemia	0.24% 2/824 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.14% 2/1428 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Metabolism and nutrition disorders Hypomagnesaemia	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 4 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Metabolism and nutrition disorders Metabolic acidosis	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.08% 2/2478 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Metabolism and nutrition disorders Hypokalaemia	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.24% 6/2478 • Number of events 6 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Metabolism and nutrition disorders Hyponatraemia	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.12% 3/2478 • Number of events 3 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Metabolism and nutrition disorders Dehydration	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.32% 8/2478 • Number of events 8 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.34% 4/1165 • Number of events 4 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.20% 2/1022 • Number of events 3 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.28% 4/1428 • Number of events 4 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Musculoskeletal and connective tissue disorders Arthritis	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Musculoskeletal and connective tissue disorders Arthritis reactive	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Musculoskeletal and connective tissue disorders Intervertebral disc compression	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Musculoskeletal and connective tissue disorders Intervertebral disc protrusion	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.12% 3/2478 • Number of events 4 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Musculoskeletal and connective tissue disorders Intervertebral disc degeneration	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Musculoskeletal and connective tissue disorders Intervertebral disc displacement	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Musculoskeletal and connective tissue disorders Rotator cuff syndrome	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Musculoskeletal and connective tissue disorders Arthralgia	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.08% 2/2478 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.26% 3/1165 • Number of events 4 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.28% 4/1428 • Number of events 5 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Musculoskeletal and connective tissue disorders Lupus-like syndrome	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.08% 2/2478 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Musculoskeletal and connective tissue disorders Systemic lupus erythematosus	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Musculoskeletal and connective tissue disorders Osteopenia	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Musculoskeletal and connective tissue disorders Fibromyalgia	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Musculoskeletal and connective tissue disorders Back pain	0.24% 2/824 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.14% 2/1428 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Musculoskeletal and connective tissue disorders Musculoskeletal pain	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.08% 2/2478 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Musculoskeletal and connective tissue disorders Neck pain	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Musculoskeletal and connective tissue disorders Pain in extremity	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Musculoskeletal and connective tissue disorders Osteoarthritis	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.14% 2/1428 • Number of events 3 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Musculoskeletal and connective tissue disorders Spinal osteoarthritis	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Musculoskeletal and connective tissue disorders Fistula	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.12% 3/2478 • Number of events 3 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Musculoskeletal and connective tissue disorders Soft tissue swelling	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Musculoskeletal and connective tissue disorders Lumbar spinal stenosis	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.08% 2/2478 • Number of events 3 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Musculoskeletal and connective tissue disorders Spinal column stenosis	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Musculoskeletal and connective tissue disorders Spondylolisthesis	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Musculoskeletal and connective tissue disorders Tenosynovitis	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Anal cancer	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Angioimmunoblastic T-cell lymphoma stage IV	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Breast cancer	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.12% 3/2478 • Number of events 3 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Breast cancer metastatic	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Breast cancer recurrent	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Breast cancer stage III	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Invasive breast carcinoma	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Adenocarcinoma of colon	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Appendix cancer	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Rectal adenocarcinoma	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Rectal cancer	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Rectal cancer stage II	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Parathyroid tumour	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Hepatic cancer metastatic	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Hepatic adenoma	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Hepatic neoplasm	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Hodgkin's disease	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.08% 2/2478 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Laryngeal squamous cell carcinoma	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Acute myeloid leukaemia	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Chronic lymphocytic leukaemia	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Lymphoma	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.14% 2/1428 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Meningioma benign	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Myelofibrosis	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Signet-ring cell carcinoma	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Lung adenocarcinoma stage I	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Oesophageal carcinoma	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Ovarian cancer	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Pancreatic carcinoma	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Prostate cancer	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.20% 2/1022 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Renal cell carcinoma stage I	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Respiratory, thoracic and mediastinal disorders Asthma	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.08% 2/2478 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.14% 2/1428 • Number of events 3 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Bronchial carcinoma	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Lung cancer metastatic	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Lung neoplasm malignant	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Rhabdomyosarcoma	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Metastatic malignant melanoma	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Basal cell carcinoma	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.08% 2/2478 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Skin cancer	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Seminoma	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Papillary thyroid cancer	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Thyroid cancer	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Uterine leiomyoma	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.08% 2/2478 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Uterine cancer	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Nervous system disorders Cerebral haemorrhage	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Nervous system disorders Cerebral infarction	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Nervous system disorders Cerebrovascular accident	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.20% 2/1022 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Nervous system disorders Cervical radiculopathy	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Nervous system disorders Ataxia	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Nervous system disorders Syncope	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.08% 2/2478 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.17% 2/1165 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.20% 2/1022 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.21% 3/1428 • Number of events 3 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Nervous system disorders Encephalopathy	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Nervous system disorders Chronic paroxysmal hemicrania	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Nervous system disorders Headache	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Nervous system disorders Idiopathic intracranial hypertension	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Nervous system disorders Status migrainosus	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Nervous system disorders Piriformis syndrome	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Nervous system disorders Amyotrophic lateral sclerosis	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Nervous system disorders Cerebrospinal fluid leakage	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Nervous system disorders Dizziness	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Nervous system disorders Hemiparesis	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Nervous system disorders Parkinson's disease	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Nervous system disorders Peripheral sensory neuropathy	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Nervous system disorders Polyneuropathy	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Nervous system disorders Febrile convulsion	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Nervous system disorders Seizure	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.24% 6/2478 • Number of events 7 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.17% 2/1165 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.14% 2/1428 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Nervous system disorders Post herpetic neuralgia	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Nervous system disorders Radicular pain	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Nervous system disorders Transient ischaemic attack	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.16% 4/2478 • Number of events 4 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Pregnancy, puerperium and perinatal conditions Abortion	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.08% 2/2478 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Pregnancy, puerperium and perinatal conditions Abortion spontaneous	0.73% 6/824 • Number of events 6 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.85% 21/2478 • Number of events 24 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.69% 8/1165 • Number of events 8 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.49% 5/1022 • Number of events 5 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.98% 14/1428 • Number of events 14 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Pregnancy, puerperium and perinatal conditions Polyhydramnios	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Pregnancy, puerperium and perinatal conditions Foetal distress syndrome	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Pregnancy, puerperium and perinatal conditions Low birth weight baby	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Pregnancy, puerperium and perinatal conditions Premature baby	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.20% 5/2478 • Number of events 5 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.14% 2/1428 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Pregnancy, puerperium and perinatal conditions Pre-eclampsia	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Pregnancy, puerperium and perinatal conditions Premature delivery	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.12% 3/2478 • Number of events 4 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Pregnancy, puerperium and perinatal conditions Retained placenta or membranes	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Pregnancy, puerperium and perinatal conditions Preterm premature rupture of membranes	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Psychiatric disorders Agitation	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Psychiatric disorders Anxiety	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Psychiatric disorders Paranoia	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Psychiatric disorders Bipolar disorder	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Psychiatric disorders Depression	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.12% 3/2478 • Number of events 3 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Psychiatric disorders Depression suicidal	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Psychiatric disorders Major depression	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Psychiatric disorders Mental status changes	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Psychiatric disorders Obsessive-compulsive disorder	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Psychiatric disorders Hallucination	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Psychiatric disorders Psychotic disorder	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Psychiatric disorders Psychogenic seizure	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.08% 2/2478 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Psychiatric disorders Alcohol problem	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Psychiatric disorders Alcoholism	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Psychiatric disorders Intentional self-injury	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Psychiatric disorders Suicidal ideation	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Renal and urinary disorders Vesical fistula	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Renal and urinary disorders IgA nephropathy	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Renal and urinary disorders Nephropathy	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Renal and urinary disorders Renal mass	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Renal and urinary disorders Acute kidney injury	0.36% 3/824 • Number of events 3 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.61% 15/2478 • Number of events 16 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.34% 4/1165 • Number of events 4 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.49% 7/1428 • Number of events 7 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Renal and urinary disorders Renal failure	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.28% 7/2478 • Number of events 7 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.14% 2/1428 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Renal and urinary disorders Chronic kidney disease	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Renal and urinary disorders Nephrolithiasis	0.36% 3/824 • Number of events 3 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.44% 11/2478 • Number of events 11 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.34% 4/1165 • Number of events 4 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.49% 7/1428 • Number of events 7 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Renal and urinary disorders Hydronephrosis	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.08% 2/2478 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Renal and urinary disorders Calculus urethral	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Renal and urinary disorders Ureterolithiasis	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.08% 2/2478 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.26% 3/1165 • Number of events 3 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.21% 3/1428 • Number of events 3 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Renal and urinary disorders Renal colic	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.08% 2/2478 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Reproductive system and breast disorders Breast enlargement	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Reproductive system and breast disorders Dysfunctional uterine bleeding	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Reproductive system and breast disorders Menstruation irregular	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Reproductive system and breast disorders Menorrhagia	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Reproductive system and breast disorders Ovarian cyst	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Reproductive system and breast disorders Hydrosalpinx	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Reproductive system and breast disorders Pelvic fluid collection	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Reproductive system and breast disorders Pelvic cyst	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.08% 2/2478 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Reproductive system and breast disorders Benign prostatic hyperplasia	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Reproductive system and breast disorders Prostatomegaly	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Reproductive system and breast disorders Female genital tract fistula	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.26% 3/1165 • Number of events 3 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.21% 3/1428 • Number of events 3 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Reproductive system and breast disorders Adenomyosis	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Reproductive system and breast disorders Endometrial hyperplasia	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Reproductive system and breast disorders Vaginal cyst	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Reproductive system and breast disorders Vaginal fistula	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Respiratory, thoracic and mediastinal disorders Dyspnoea	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.08% 2/2478 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Reproductive system and breast disorders Vaginal haemorrhage	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Respiratory, thoracic and mediastinal disorders Chronic obstructive pulmonary disease	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Respiratory, thoracic and mediastinal disorders Pneumonia aspiration	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Respiratory, thoracic and mediastinal disorders Pneumonitis	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Respiratory, thoracic and mediastinal disorders Pleuritic pain	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.08% 2/2478 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Respiratory, thoracic and mediastinal disorders Neonatal aspiration	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Respiratory, thoracic and mediastinal disorders Tonsillar hypertrophy	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Respiratory, thoracic and mediastinal disorders Haemothorax	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Respiratory, thoracic and mediastinal disorders Pneumothorax	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Respiratory, thoracic and mediastinal disorders Acute respiratory distress syndrome	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Surgical and medical procedures Elective surgery	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Respiratory, thoracic and mediastinal disorders Pulmonary embolism	0.24% 2/824 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.24% 6/2478 • Number of events 6 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.43% 5/1165 • Number of events 5 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.49% 7/1428 • Number of events 7 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Respiratory, thoracic and mediastinal disorders Acute respiratory failure	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Respiratory, thoracic and mediastinal disorders Respiratory failure	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.08% 2/2478 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Respiratory, thoracic and mediastinal disorders Lung disorder	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Skin and subcutaneous tissue disorders Angioedema	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Skin and subcutaneous tissue disorders Metastatic cutaneous	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.08% 2/2478 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Skin and subcutaneous tissue disorders Rash pruritic	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Skin and subcutaneous tissue disorders Rash maculo-papular	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Skin and subcutaneous tissue disorders Pyoderma gangrenosum	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.08% 2/2478 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Skin and subcutaneous tissue disorders Haemorrhage subcutaneous	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Social circumstances Victim of homicide	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Surgical and medical procedures Abdominal wall operation	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Surgical and medical procedures Explorative laparotomy	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Surgical and medical procedures Proctectomy	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.08% 2/2478 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Surgical and medical procedures Carotid endarterectomy	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Surgical and medical procedures Coronary arterial stent insertion	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Surgical and medical procedures Coronary artery bypass	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Surgical and medical procedures Cholecystectomy	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.08% 2/2478 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.14% 2/1428 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Surgical and medical procedures Transfusion	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.17% 2/1165 • Number of events 3 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.14% 2/1428 • Number of events 3 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Surgical and medical procedures Breast reconstruction	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Surgical and medical procedures Chemotherapy	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Surgical and medical procedures Fluid replacement	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Surgical and medical procedures Drug detoxification	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Surgical and medical procedures Gastrectomy	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Surgical and medical procedures Ileocolectomy	0.24% 2/824 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.28% 7/2478 • Number of events 7 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.17% 2/1165 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.28% 4/1428 • Number of events 4 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Surgical and medical procedures Intestinal resection	0.24% 2/824 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.48% 12/2478 • Number of events 12 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.34% 4/1165 • Number of events 4 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.42% 6/1428 • Number of events 6 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Surgical and medical procedures Enterostomy	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.08% 2/2478 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Surgical and medical procedures Intestinal anastomosis	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.08% 2/2478 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Surgical and medical procedures Intestinal operation	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Surgical and medical procedures Abortion induced	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.16% 4/2478 • Number of events 4 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Surgical and medical procedures Hip arthroplasty	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Surgical and medical procedures Hip surgery	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Surgical and medical procedures Knee arthroplasty	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Surgical and medical procedures Knee operation	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Surgical and medical procedures Shoulder arthroplasty	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Surgical and medical procedures Wrist surgery	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Surgical and medical procedures Appendicectomy	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Surgical and medical procedures Caecum operation	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Surgical and medical procedures Colectomy	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.24% 6/2478 • Number of events 6 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.20% 2/1022 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Surgical and medical procedures Colectomy total	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.08% 2/2478 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Surgical and medical procedures Pelvic pouch procedure	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.08% 2/2478 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Surgical and medical procedures Proctocolectomy	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.08% 2/2478 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Surgical and medical procedures Caesarean section	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.14% 2/1428 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Surgical and medical procedures Drug rehabilitation	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Surgical and medical procedures Ileectomy	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.08% 2/2478 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Surgical and medical procedures Ileostomy	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.20% 5/2478 • Number of events 5 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.39% 4/1022 • Number of events 4 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Surgical and medical procedures Ileostomy closure	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.08% 2/2478 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.14% 2/1428 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Surgical and medical procedures Small intestinal resection	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.16% 4/2478 • Number of events 4 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Surgical and medical procedures Small intestine operation	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Surgical and medical procedures Spinal fusion surgery	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Surgical and medical procedures Surgery	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.12% 3/2478 • Number of events 3 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Surgical and medical procedures Adhesiolysis	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Surgical and medical procedures Stoma closure	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Surgical and medical procedures Hysterectomy	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.08% 2/2478 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Vascular disorders Hypertensive crisis	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Vascular disorders Aortic dissection	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Vascular disorders Aortic stenosis	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Vascular disorders Hypovolaemic shock	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Vascular disorders Shock	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Vascular disorders Embolism arterial	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Vascular disorders Thrombosis	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/2478 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Vascular disorders Deep vein thrombosis	0.12% 1/824 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.32% 8/2478 • Number of events 8 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.52% 6/1165 • Number of events 7 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.49% 7/1428 • Number of events 8 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Vascular disorders Peripheral artery thrombosis	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Vascular disorders Thrombophlebitis	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.08% 2/2478 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Vascular disorders Essential hypertension	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Vascular disorders Hypertension	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Vascular disorders Granulomatosis with polyangiitis	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.04% 1/2478 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1165 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1022 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.00% 0/1428 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.

Other adverse events

Other adverse events
Measure	Cimzia n=824 participants at risk Participants (exposure and events) while receiving Cimzia® only including the half-life of Cimzia® without comparator including half-life of comparator. Participants may be included in treatment groups.	Comparator n=2478 participants at risk Participants (exposure and events) while receiving corticosteroids, immunosuppressants or other biologics (e.g. anti-TNFs) other than Cimzia®, alone or in combination with each other including their half-life. Participants may be included in other treatment groups.	Overlap n=1165 participants at risk Participants (exposure and events) while receiving Cimzia® along with corticosteroids, immunosuppressants or other biologics (e.g. anti-TNFs) other than Cimzia® including the half-life time of Cimzia® and the comparator. Participants may be included in other treatment groups.	Gap (No Cimzia and no Comparator at Baseline) n=1022 participants at risk Participants (exposure and events) neither receiving Cimzia® (including the half-life of Cimzia®) nor receiving comparator (including the half-life).	Cimzia + Overlap n=1428 participants at risk Participants who received Cimzia® monotherapy or Cimzia® in combination with comparison treatment were included in this group. Participants may be included in other treatment groups.
Gastrointestinal disorders Crohn's disease	0.73% 6/824 • Number of events 7 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.52% 13/2478 • Number of events 13 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.94% 11/1165 • Number of events 12 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	1.2% 17/1428 • Number of events 19 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Gastrointestinal disorders Abdominal pain	0.73% 6/824 • Number of events 6 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.52% 13/2478 • Number of events 16 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.52% 6/1165 • Number of events 6 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.77% 11/1428 • Number of events 12 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Clostridium difficile infection	0.36% 3/824 • Number of events 4 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.52% 13/2478 • Number of events 21 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.52% 6/1165 • Number of events 6 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.63% 9/1428 • Number of events 10 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Infections and infestations Herpes zoster	0.24% 2/824 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.77% 19/2478 • Number of events 19 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.43% 5/1165 • Number of events 5 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.29% 3/1022 • Number of events 3 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.49% 7/1428 • Number of events 7 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Musculoskeletal and connective tissue disorders Arthralgia	0.61% 5/824 • Number of events 6 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.32% 8/2478 • Number of events 9 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.43% 5/1165 • Number of events 5 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.20% 2/1022 • Number of events 2 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.70% 10/1428 • Number of events 11 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Basal cell carcinoma	0.00% 0/824 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.52% 13/2478 • Number of events 13 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.09% 1/1165 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.10% 1/1022 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.	0.07% 1/1428 • Number of events 1 • From Baseline up to 10 years Treatment-Emergent adverse events (TEAEs) were defined as those events which first occurred or increased in relationship to treatment after the first dose of any crohn's disease drug following enrollment. Participants were counted in more than one arm based on the various treatments they actually received and presented based on acute event rules. Based upon planned analysis of acute event rules, TEAEs are reported for Cimzia®, Comparator, Overlap, Gap and Any Cimzia® reporting groups.

Additional Information

UCB

Cares

Phone: 001 844 599 2273

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee
Publication restrictions are in place

Restriction type: GT60